Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Accenture
Queensland Health
Harvard Business School
QuintilesIMS
Cipla

Generated: March 23, 2019

DrugPatentWatch Database Preview

Ani Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ANI PHARMS INC, and when can generic versions of ANI PHARMS INC drugs launch?

ANI PHARMS INC has one hundred and fifty-five approved drugs.

There is one US patent protecting ANI PHARMS INC drugs.

There are fourteen patent family members on ANI PHARMS INC drugs in eleven countries and thirty-one supplementary protection certificates in nine countries.

Summary for Ani Pharms Inc
International Patents:14
US Patents:1
Tradenames:90
Ingredients:86
NDAs:155

Drugs and US Patents for Ani Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc SULFAMETHOXAZOLE AND TRIMETHOPRIM sulfamethoxazole; trimethoprim SUSPENSION;ORAL 077612-001 Nov 13, 2006 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc NEFAZODONE HYDROCHLORIDE nefazodone hydrochloride TABLET;ORAL 076072-004 Sep 16, 2003 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc MEXILETINE HYDROCHLORIDE mexiletine hydrochloride CAPSULE;ORAL 074450-001 May 16, 1996 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc PRAZOSIN HYDROCHLORIDE prazosin hydrochloride CAPSULE;ORAL 072577-002 May 16, 1989 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc CEFADROXIL cefadroxil/cefadroxil hemihydrate FOR SUSPENSION;ORAL 062698-001 Mar 1, 1989 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc CLARITHROMYCIN clarithromycin TABLET, EXTENDED RELEASE;ORAL 065250-001 Aug 25, 2005 DISCN No No ➤ Sign Up ➤ Sign Up
Ani Pharms Inc INDAPAMIDE indapamide TABLET;ORAL 074299-002 Apr 29, 1996 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Ani Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms Inc ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 5,703,110 ➤ Sign Up
Ani Pharms Inc ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-002 Sep 5, 2000 5,705,517*PED ➤ Sign Up
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 5,196,444*PED ➤ Sign Up
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-003 Jun 4, 1998 5,705,517*PED ➤ Sign Up
Ani Pharms Inc ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-001 Sep 5, 2000 5,721,263 ➤ Sign Up
Ani Pharms Inc CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 5,712,251 ➤ Sign Up
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-004 Jun 4, 1998 5,534,534*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ANI PHARMS INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 16 mg/12.5 mg and 32 mg/12.5 mg ➤ Subscribe 2008-06-25
➤ Subscribe Tablets 4 mg, 8 mg, 16 mg and 32 mg ➤ Subscribe 2006-12-22
➤ Subscribe Tablets 32 mg/25 mg ➤ Subscribe 2009-03-06

Supplementary Protection Certificates for Ani Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0459136 8/1998 Austria ➤ Sign Up PRODUCT NAME: CANDESARTAN CILEXETIL ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 1-22232, 1-22233, 1-22235, 1-22236 19971119; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
0459136 98C0016 Belgium ➤ Sign Up PRODUCT NAME: CANDESARTAN CILEXETIL; NAT. REGISTRATION NO/DATE: 212 IS 236 F3 19980119; FIRST REGISTRATION: GB PL 15661/0001 19970429
0473687 SPC/GB98/030 United Kingdom ➤ Sign Up PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0459136 C970044 Netherlands ➤ Sign Up PRODUCT NAME: CANDESARTAN, DESGENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF VAN DE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYLESTE R, IN HET BIJZONDER CILEXETILI CANDESARTANAS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 21703 - RVG 21706 19971013; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
0454511 99C0009 Belgium ➤ Sign Up PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0196132 94C0008 Belgium ➤ Sign Up PRODUCT NAME: RISPERIDONE; NAT REG.: 2 S 414 F 3 19940527; FIRST REG.: GB 0242/0186 19921208
0503785 CA 2011 00026 Denmark ➤ Sign Up PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Accenture
Baxter
Queensland Health
Merck
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.